To summarize the advances in antibiotic therapy for infection after the surgical installation of implants to treat internal fractures. Recent studies on antibiotic therapy for infection after the surgical installation of implants to internal fractures were reviewed and analyzed. In general, systematic antibiotics are selected based on the results of bacterial culture. The duration of antibiotic treatment lasts for no more than 4 to 6 weeks. Orally administered and intravenously injected antibiotics have similar efficacies. Orally administered antibiotics exhibit a lower incidence of complications and are less costly than intravenously injected antibiotics. In addition, the efficacy of daptomycin in the treatment of bone infection is problematic. Rifampicin or fluoroquinolone antibiotics should be jointly administered when infection with bacterial biofilms is likely to occur. Calcium sulfate is a typical topically applied antibiotic delivery vehicle that can be completely degraded, with good biocompatibility, bone conduction, and drug release. The rational, systematic, and combined topical application of antibiotics can effectively decrease the recurrence rates of infection after the surgical installation of implants to treat internal fractures and can improve the quality of life of patients.
Postoperative infection has become increasingly common with the increasing use of surgery to treat internal fractures. According to the literature, the incidence rate of infection after the surgical installation of implants to treat internal fractures is 0.4% to 16.1%, with an average of approximately 5% [1] . The incidence of infection after the surgical treatment of closed internal fracture is 0.5% to 2% [2] , whereas that after open fracture is 1% to 55% [3] . The more severe the injury, the higher the risk of infection. Infection after the surgical treatment of internal fractures is also one of the most serious challenges that orthopedic surgeons face. The difficulty in controlling infection lies in the complex, difficult treatment and high recurrence rates of infection. Antibiotics have a vital role in the treatment of infection after implantation surgeries. The early and judicious use of antibiotics can significantly decrease the recurrence rate of infection and improve the quality of life of patients. This paper provides a review of the recent advances in antibiotic therapy for post-operative infection after the surgical installation of implants to treat internal fractures.
Classification of infection after the surgical installation of implants to treat internal fractures
Based on the source of infection [2] Perioperative period infection: infection caused by wound contamination or surgery; Adjacent lesions: infection caused by penetrating trauma, such as in open fractures and adjacent lesions;
Hematogenous transmission: infection caused by distant tissue or organ infection and transmitted through blood flow or lymph.
Based on the time of occurrence of postoperative infection [ 
1-2]
Early infection: acute phase. Infection occurs 2 to 3 weeks after surger y and is mostly caused by the infection of wounds or surgical incisions. The pathogens are mostly virulent microorganisms, such as Staphylococcus aureus and Gram-negative bacilli.
Delayed infection: subacute phase. Infection occurs 2 to 10 weeks after surgery and is caused by trauma or internal fixation. During the period, the majority of bacteria begin to form a stable biofilm.
Chronic infection: chronic phase. Infection occurs 10 weeks after surgery. The pathogens are mostly hypovirulent microorganisms, such as coagulase-negative staphylococci. Sometimes the infection is transmitted through blood. Infection mainly manifests as chronic osteomyelitis. [4] This type consists of the anatomical and host types.
Cierny-Mader type of chronic osteomyelitis (1984)
Based on the extent of infection, the anatomical type can be divided into four sub-types: intramedullary, superficial, circumscribed, and dispersive.
Based on the host's immune status, the host type can be divided into three sub-types: type A for healthy patients who exhibit no other infection except for the osteomyelitis lesion itself; type B for patients with jointly inf luential wound healing disease, including local lesions and systemic disease; and type C for patients with immunodeficiency or similar health problems.
Advances in systemic antibiotic therapy
Time and method of therapy Clinical guidelines for the traditional treatment method recommend 6 week s of a nt ibiot ics ad m in istered v ia intravenous injection when infection is combined with osteomyelitis [5] . Recent studies, however, have shown that as long as the pathogen is sensitive to antibiotics, the efficacy of intravenous injection is similar to that of oral antibiotics, and that oral antibiotics have fewer side effects and are less costly than intravenously injected antibiotics [5 -6] . I n add it ion, no su f f ic ient ev idence e x ist s t hat administering antibiotic therapy for more than 4 to 6 weeks benefits the patient. Recently, the results of a multicenter, prospective, and randomized controlled study has also shown that 6 weeks of antibiotic therapy is sufficient for osteomyelitis caused by diabetes and that the use of antibiotics should not be prolonged [7] .
Selection of systematic antibiotics
T he penetration and coverage of antibiotics in bone tissue are key factors in the effective treatment of bone infections [8] and are impor tant reference factors for the selection of antibiotics. In addition, the selection of antibiotics for sensitive pathogens is also important. S. aureus and β-hemolytic streptococcus dominate the acute phase of infection [9] . The use of β-lactam antibiotics alone or combined with aminoglycoside antibiotics will achieve satisfactory results in most patients [10] . W hen MRSA infection is suspected, glycopeptide antibiotics or daptomycin should be preferentially administered and can also be used together to improve the efficacy of rifampicin. One important feature of the sub-acute and chronic phases of infection after internal fixation surgeries is the formation of bacterial biofilms. The pathogenesis of bacterial biofilms has two main aspects: (1) Antagonize immunity, thus causing chronic infection. (2) The special structure of bacterial biofilms requires a high minimum concentration of antibiotics for treatment. The required minimum concentration for bacterial biofilms can reach 10 to 1,000 times that for planktonic bacteria. Many bacteria and fungi can form biofilms. The most common biofilmforming bacterial species include S. aureus, S. epidermidis, type-A streptococci, and Pseudomonas aeruginosa; yeast can also form biofilms. [11] . Rifampicin and rifamycin are the two antibiotics that can effectively clear bacterial biofilms formed by Staphylococcus species [12] . Fluoroquinolone antibiotics can effectively remove biofilms formed by Gram-negative bacteria [13] .
Daptomycin has attracted increased research attention. Many studies have reported its efficacy in the treatment of bone infections. Seaton et al. [14] conducted a multi-center, retrospective study that involved 220 patients. Their results showed that daptomycin effectively treats osteomyelitis and is well tolerated in patients; it may be more effective combined with surgical intervention. Through a casecontrol study, Liang et al. [15] found that the clinical efficacy and tolerability of daptomycin are equivalent to that of vancomycin in the treatment of MRSA-induced bone and joint infection. Therefore, the replacement of vancomycin by daptomyci n i n t he t reat ment of bone i n fec t ions caused by MRSA is recommended if the patient cannot tolerate vancomycin. A randomized controlled clinical study by Byren et al. [16] found that in the treatment of prosthesis infections caused by S. aureus, the efficacy of the continuous use of 6 mg/kg or 8 mg/kg daptomycin for 6 weeks is similar to those of traditional antibiotics, such as vancomycin, teicoplanin, and semi-sy nthetic penicillin, and that using daptomycin is safe. In addition to systemic use, daptomycin can also be loaded on antibiotic deliver y vehicles for topical anti-infective treatment. R osslenbroich et al . [17] combi ned daptomyc i n w it h traditional polymethylmethacrylate (PMMA) bone cement for the topical application of daptomycin after the surgical treatment of fractions and complicated osteomyelitis. T he combined methomycin and PM M A reta in their antimicrobial properties and the structural characteristics of the PM M A deliver y vehicle are not compromised. Therefore, daptomycin could be used in combination with antibiotic delivery vehicles for the topical treatment of bone infections. However, given the limited clinical reports on daptomycin, its clinical efficacy in the treatment of bone infection still requires further in-depth study.
Research on delivery vehicles for topical antibiotics
Antibiotics are mainly applied in the treatment of chronic osteomyelitis. Topical bone ischemia, sclerosis, and softtissue scarring occur due to chronic osteomyelitis, and thus the blood supply is inadequate at the lesion site. Sometimes, systemic antibiotics do not reach the effective sterilization concentration; this effect is often combined with bone nonunion. Bone defects often occur after surgical debridement to remove sequestra. Therefore, the topical application of the appropriate antibiotic delivery vehicle can repair the defect, close the dead cavity, prevent the formation of cicatrix, and kill or inhibit bacteria. P M M A b o n e c e m e n t i s t h e m o s t c o m m o n l y u sed a nt ibiot ic del iver y veh icle [18] . Given it s poor biocompatibility and low release rate, it cannot self-degrade in the body and must be removed via surgery. Therefore, the shortcomings of PM M A necessitate the research and development of a highly efficient and biodegradable antibiotic deliver y vehicle. Calcium sulfate can meet the requirements for a biodegrable antibiotic delivery vehicle: good bio-compatibility, complete degradation, and capability for bone conduction and drug release. In addition, calcium sulfate will not produce excessive heat when mixed with solutions, thus effectively preserving antibiotic activ it y [19] . I n recent years, many studies have compared the relevant characteristics of calcium sulfate as an antibiotic deliver y vehicle with those of PMMA. The results of an in vitro experiment conducted by McConoug hey e t al . [2 0] showed t hat t he topica l antimicrobial capacity of calcium sulfate is similar to or even better than that of PMMA. In a clinical randomized controlled trial that compared the efficacy of PMMA and calcium sulfate as topical antibiotic delivery vehicles in the treatment of chronic osteomyelitis and infected nonunion, McKee et al. [21] found that the efficacy of calcium sulfate is similar to that of PMM A in the removal of infection. However, because calcium sulfate is biodegradable, the required number of operations for the removal of calcium sulfate is less than that for the removal of PMM A. An animal experiment by Beenken et al. [22] showed that as an antibiotic delivery vehicle, chitosan-coated calcium sulfate improves the release of sustained-release drugs and exhibits satisfactory efficacy in the treatment of osteomyelitis. Calcium sulfate does have shortcomings. Guler et al. [23] pointed out that calcium sulfate is weaker than PMMA. Nevertheless, in recent years, the Traumatic Orthopedics Depa r t ment of Na n fa ng Hospita l ha s used ca lciu m sulfate as an antibiotic delivery vehicle for gentamicin or vancomycin and in combination with bone transport for the treatment of chronic osteomyelitis and infected nonunion. The use of calcium sulfate in these cases has been highly effective.
In addition, many studies have reported the efficacy of other types of antibiotic delivery vehicles in the treatment of osteomyelitis. Cui et al. [24] developed a novel injectable borate bioactive glass cement loaded with vancomycin.
The results of an in vitro test showed that the cure rate of this delivery vehicle in osteomyelitis is 87%. Similarly, an in vitro test by Ding et al. [25] proved that boric acid cement loaded with vancomycin and calcium sulfate loaded with vancomycin are superior to simple intravenous injection in the treatment of MRSA-induced osteomyelitis, and t hat borate bone cement has good biocompat ibi l it y and capability to promote bone regeneration. A nimal experiments and clinical trials by Bhattacharya et al. [26] showed that the use of porous hydroxyapatite stent loaded with ceftriaxone and sulbactam sodium can effectively treat osteomyelitis, reduce the recurrence rate of infection, and promote bone regeneration. Animal experiments by Kaya et al. [27] showed that calcium hydroxyapatite loaded with tigecycline is effective in treating osteomyelitis caused by MRSA. Although these studies demonstrated the effectiveness of various antibiotic delivery vehicle systems in the treatment of chronic osteomyelitis, most of the results came from animal experiments. Therefore, the reported results of these clinical trials are limited. With regard to future trends, Kluin et al. [28] suggested that an ideal antibiotic delivery vehicle for the treatment of osteomyelitis should have good biocompatibility, controlled degradation kinetics, and can load and release any antibiotic under strict conditions (longer times, higher topical concentrations), with preferably level zero release kinetics. A lthough PMM A is the most commonly used delivery vehicle in the treatment of chronic osteomyelitis, it is not the best delivery vehicle because of its non-degradability and poor release properties. Biodegradable collagen and calcium matrix delivery vehicles can release large amounts of antibiotics within 24 h after implantation; thus, the prolonged release of antibiotics cannot be guaranteed with these vehicles. In addition, collagen and calcium sulfate can absorb water and promote the formation of hematomas, thus increasing the risk of superinfection. Among the types of polylactic acid and polyglycolic acid (PGLA) delivery vehicles, PLGA exhibits the best release characteristics. All delivery vehicles, however, can produce acidic degradation products that cause bone resorption. Therefore, based on the recommended level zero release kinetic theory and for the prevention of acidic degradation, trimethylene carbonate could replace lactic acid and PLGA.
Other issues related to the treatment of infection after the surgical installation of implants to treat internal fractures A lthough antibiotics are essential for the treatment of infection after the surgical installation of implants to treat internal fractures, the application of systemic and topical antibiotics must be based on the thorough debridement of the infected lesion. Otherwise, antibiotic treatment will not be effective [2, 5, 10] . In addition, the reasonable handling of internal fixation also determines the efficacy of antibiotics in patients; during different infection periods, the disposal strategy of internal fixation is not the same. For acute-phase infection, there is no recommendation based on medical ev idence on the retention or removal of the internal fixation. However, most scholars suggest that reservations be made as much as possible in the context of stable internal fixation. The removal of internal fixations is advisable in the following situations: (1) when installed in drug addicts or heavy smokers; (2) open fracture; (3) and intramedullary fixation [29] . Therefore, during the acute phase, if the internal fixation of the patient is stable, the anti-infective treatment must be strengthened. In addition, infection indexes must be followed up; if local and systemic infection is effectively controlled, internal fixation can be retained temporarily; otherwise, it should be removed as early as possible. During sub-acute and chronic phases of infection, if the fracture has been healed, internal fixation should be promptly removed. Internal fixation should be retained only when stable, the infection is effectively controlled, and conditions of local soft tissue are good [29] .
Summary
I n fect ion a f ter t he su rg ica l i nsta l lat ion of i mpla nts to treat i nter na l f ract ures is a complex d isease, and mu lt id iscipl i na r y col laborat ion is benef icia l for t he treatment of patients [30] . Antibiotics are an integral part of the treatment of bone infections. The early and appropriate application of antibiotics can significantly reduce the recurrence rate of infection and improve the quality of life of patients.
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